​

Tevogen Bio Stock (NASDAQ:TVGN)

RevenueOwnershipFinancialsChart
Tevogen Bio by TradingView

Previous Close

$0.72

52W Range

$0.64 - $3.09

50D Avg

$0.84

200D Avg

$1.11

Market Cap

$138.01M

Avg Vol (3M)

$835.41K

Beta

-0.81

Div Yield

-

TVGN Company Profile

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

18

IPO Date

Jan 05, 2022

Website

TVGN Performance

TVGN Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-53.56M$-8.84K$-13.72M
Net Income$-13.73M$-67.33K$4.41M
EBITDA$-53.56M$188.71K$-953.08K
Basic EPS$-0.09-$0.04
Diluted EPS$-0.09-$0.04

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
MOLNMolecular Partners AG
CCCCC4 Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
GLSIGreenwich LifeSciences, Inc.
CGTXCognition Therapeutics, Inc.
ANROAlto Neuroscience, Inc.
ATOSAtossa Therapeutics, Inc.
NVCTNuvectis Pharma, Inc.
PEPGPepGen Inc.